Pluristem Therapeutics, Inc. Announces Its Sr. VP of Corporate Development Will Be Presenting at the Accredited Members Sprin...
February 25 2013 - 11:46AM
Marketwired
HAIFA,
ISRAEL--(Marketwire - February 25, 2013) -
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) (TASE: PLTR), a leading
developer of placenta-based cell therapies, announced today that
William R. Prather RPh, MD, its Senior VP of Corporate Development,
will be presenting the Company at the Accredited Members Spring
Small Cap/Micro Cap Conference, being held at the JW Marriott
Resort and Spa on February 27th, 28th and March 1st. Dr. Prather will be
presenting at 11:18 AM on February 28, 2013 in the Public Hall. Dr.
Prather will also be available before and after his presentation to
answer questions concerning Pluristem.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of
placenta-based cell therapies. The Company's patented PLX
(PLacental eXpanded) cells are a drug delivery platform that
releases a cocktail of therapeutic proteins in response to a host
of local and systemic inflammatory and ischemic diseases. PLX cells
are grown using the company's proprietary 3D micro-environmental
technology and are an "off-the-shelf" product that requires no
tissue matching prior to administration.
Pluristem has a strong patent and patent applications portfolio,
company-owned GMP certified manufacturing and research facilities,
strategic relationships with major research institutions and a
seasoned management team. For more information visit
www.pluristem.com, the content of which is not part of this press
release.
Safe Harbor Statement This
press release may contain forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995 and federal securities laws. These
forward-looking statements are based on the current expectations of
the management of Pluristem only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
The following factors, among others, could cause actual results to
differ materially from those described in the forward-looking
statements: changes in technology and market requirements; we may
encounter delays or obstacles in launching and/or successfully
completing our clinical trials; our products may not be approved by
regulatory agencies, our technology may not be validated as we
progress further and our methods may not be accepted by the
scientific community; we may be unable to retain or attract key
employees whose knowledge is essential to the development of our
products; unforeseen scientific difficulties may develop with our
process; our products may wind up being more expensive than we
anticipate; results in the laboratory may not translate to equally
good results in real surgical settings; results of preclinical
studies may not correlate with the results of human clinical
trials; our patents may not be sufficient; our products may harm
recipients; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; loss of
market share and pressure on pricing resulting from competition,
which could cause the actual results or performance of Pluristem to
differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Pluristem, reference is made to Pluristem's
reports filed from time to time with the Securities and Exchange
Commission.
Contact: Pluristem Therapeutics Inc.:William Prather
R.Ph., M.D. Sr. VP Corporate Development 1-303-883-4954
William.PratherMD@pluristem.comDaya Lettvin Investor & Media
Relations Director +972-54-674-5580 daya@pluristem.com
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Aug 2023 to Aug 2024